Tumor aggression-defense index-a novel indicator to predicts recurrence and survival in stage II-III colorectal cancer.

ABSTRACT:

Background

Although the TNM staging system plays a critical role in guiding adjuvant chemotherapy for colorectal cancer (CRC), its precision for risk stratification in stage II and III CRC patients with proficient DNA mismatch repair (pMMR) remains limited. Therefore, precise predictive models and research on postoperative treatments are crucial for enhancing patient survival and improving quality of life.

Methods

This retrospective study analyzed 1051 pMMR CRC patients who underwent radical resection and were randomly assigned to training (n = 736) and validation (n = 315) groups. Immunohistochemistry and hematoxylin and eosin staining were utilized to evaluate regulatory-Immunoscore (RIS), tertiary lymphoid structures (TLS), and tumor budding (TB). The Tumor Aggression-Def

SUBMITTER: Wu T 

PROVIDER: S-EPMC11755833 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature